ClinicalTrials.gg
RecruitingNCT07604766RAINFOL-02Updated Nov 3, 2026

An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China

A Phase 3 interventional study of Rina-S and Paclitaxel in Platinum-resistant Ovarian Cancer, sponsored by Genmab. Recruiting at 17 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Genmab · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 393 studies in Ovarian Neoplasms with a site in China — 199 open to participants now, 231 under way, 36 of them phase 3. Ovarian Neoplasms · China.

Planned enrollment
162nd of 320
82 · median 83
Started
2026
with 42 others
Phase 3
53 of 393
20 open now
Primary completion
2027-09
later than 143 of 230 live
Registered
362nd of 393
by date

Among the 393 studies in Ovarian Neoplasms with a site in China, this one is the 162nd largest by planned enrollment of the 320 interventional ones that give a count, is one of 43 that started in 2026, is one of 53 in phase 3, reaches primary completion later than 143 of the 230 other live ones, and was the 362nd registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

199 of the 393 studies in Ovarian Neoplasms with a site in China are open now. Recruiting first, the newest first:

193 more — sign in →

All 199 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 393 studies in Ovarian Neoplasms with a site in China, or all of them as a file.
02

Study summary

The purpose of this Chinese extension study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer.

Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose.

All participants will receive active drug; no one will be given placebo.

This study is an extension study of the protocol GCT1184-02 (NCT06619236).

03

Conditions studied

  • Platinum-resistant Ovarian Cancer

Keywords

  • antibody-drug conjugate
  • folate receptor alpha (FRα)
  • ovarian cancer
  • fallopian tube cancer
  • primary peritoneal cancer
  • folate receptor
  • platinum-resistant ovarian cancer (PROC)
  • rinatabart sesutecan
  • Topoisomerase 1 inhibitor
  • PRO1184
  • GEN1184
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants must have or cytologically confirmed high grade serous or endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
  • Participants may be enrolled regardless of FRα expression level.
  • Participants must have received 1 to 4 . Participants must have progressed radiographically on or after their most recent line of therapy.
  • Participants must have received prior treatment with the following therapies:

    • Platinum chemotherapy
    • Prior bevacizumab (or biosimilar) treatment is required, if labeled and available as standard of care per institutional guidelines, unless the participant has a documented or unless the participant is not eligible for treatment with bevacizumab (or biosimilar) due to precautions/intolerance
    • Participants with known or suspected deleterious germline or somatic breast cancer gene (BRCA) mutations and who achieved a complete or partial response to platinum-based chemotherapy must have been treated with a poly ADP-ribose polymerase (PARP) inhibitor as maintenance treatment unless the participant is not eligible for treatment with PARP inhibitor
  • Mirvetuximab soravtansine, if:

    • Mirvetuximab soravtansine is available in the enrollment region, and
    • The participant is eligible, and
    • The participant does not have a documented medical exception, including chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and /or monocular vision.
  • Participants must have platinum-resistant disease:

    • Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum therapy, and must have either had a response (CR or PR) or had non- at the start of platinum-based therapy, and then progressed between > 91 days and ≤ 183 days after the date of the last dose of platinum.
    • Participants who have received a protocol defined number of lines of platinum-based therapy must have progressed on or within 183 days after the date of the last dose of platinum.

Key Exclusion Criteria:

  • Prior therapy with an antibody-drug conjugate containing a topoisomerase 1 inhibitor.
  • Have primary platinum- disease, defined as ovarian cancer that did not respond (CR or PR) to or progressed ≤ 91 days after the last dose of a first-line platinum-containing regimen.
  • History of another within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of or death (e.g., 5-year OS ≥90%), including, but not limited to, adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, ductal carcinoma in situ, or Stage I uterine cancer.
  • Known active central nervous system metastases or carcinomatous meningitis. Participants with previously treated may participate provided they are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment, they have no new or enlarging brain metastases, and are off and anticonvulsants prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study drug. Participants with suspected brain metastases at screening should undergo a computed tomography (CT)/magnetic resonance imaging (MRI) of the brain prior to study entry.
  • Hospitalization or clinical symptoms due to gastrointestinal obstruction within the past 91 days or radiographic evidence of gastrointestinal obstruction at the time of screening. Enrollment of participants who currently require parenteral nutrition must be discussed with the study medical monitor to determine eligibility.
  • Participant has ascites/pleural effusion. Enrollment of participants with an indwelling catheter flush/drain is not allowed. Note: Clinically significant is defined as (1) symptomatic, or (2) requires therapeutic paracentesis/thoracentesis within 8 weeks of the first dose, or (3) recurrent ascites/pleural effusion that necessitates multiple paracentesis/thoracocentesis procedures more often than approximately every 4 weeks.

NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    Rina-S

    Drug: Rina-S

  • Active comparator
    Investigator's Choice

    Drug: Paclitaxel · Drug: Topotecan · Drug: Pegylated liposomal doxorubicin (PLD) · Drug: Gemcitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the time from the date of randomization to the date of the first documented progression or death (PD) due to any cause, whichever occurs first based on response evaluation criteria in solid tumors (RECIST) version 1.1 as assessed by the investigator.

    Time frame: Up to approximately 16 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from date of randomization to date of death due to any cause.

    Time frame: Up to approximately 25 months

  2. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) based on RECIST v1.1 as assessed by the investigator.

    Time frame: Up to approximately 25 months

  3. PFS as Determined by BICR

    PFS is defined as the time from the date of randomization to the date of the first documented progression or death (PD) due to any cause, whichever occurs first based on RECIST version 1.1 as determined by BICR.

    Time frame: Up to approximately 16 months

  4. ORR as Determined by BICR

    ORR is defined as the percentage of participants with BOR of CR or PR based on RECIST v1.1 as determined by BICR.

    Time frame: Up to approximately 25 months

  5. Duration of Response (DOR)

    DOR is defined as the time from the onset date of response to the date of the first documented progression or death due to any cause based on RECIST v1.1 as assessed by the investigator and by blinded independent central review (BICR).

    Time frame: Up to approximately 25 months

  6. Percentage of Participants Who Achieved Cancer Antigen-125 (CA-125) Response per Gynecologic Cancer Intergroup (GCIG) Criteria

    A CA-125 response per the GCIG criteria is defined as a ≥ 50% reduction in CA-125 levels from baseline.

    Time frame: Up to approximately 25 months

  7. Time to Second Disease Progression or Death From any Cause (PFS2)

    PFS2 is defined as the time from randomization to the date of the second PD (i.e., the first PD reported in subsequent anti-cancer therapies, or long-term follow up) or death.

    Time frame: Up to approximately 25 months

  8. Overall Change From Baseline in Global Health Status/Quality of Life (GHS/Qol)

    Overall change from baseline in GHS/Qol score (items 29 and 30) will be calculated using the European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC-QLQ-C30) questionnaire. The score ranges from 0 to 100. A high scale score represents a higher response level.

    Time frame: Baseline, up to approximately 25 months

  9. Time to Deterioration (TTD) in the GHS/Qol Score

    TTD in the GHS/Qol score is defined as the time from baseline to the first onset of a ≥10-point negative change (decrease) in GHS/QoL score. A longer TTD indicates a better outcome.

    Time frame: Up to approximately 25 months

  10. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 25 months

07

Study locations

17 of 17 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Sep 2027, 15 months after the start.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 15 months is below that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
May 22, 2026
StartActual
Jun 26, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07604766
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
May 22, 2026
Start date
Jun 26, 2026
Primary completion
Sep 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Genmab Trial Information
Contact
clinicaltrials@genmab.com
+4570202728
Study Official
study director · Genmab

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rinatabart sesutecan

Start the discussion